Can health plans afford to ignore tobacco harm reduction?
Health insurance companies have always been ambivalent about treatment of cigarette smokers. Tobacco-related disease accounts for roughly 8 percent of U.S. medical spending, while smoking cessation is among the most cost-effective interventions in medicine. Yet the economics look different from…
Health insurance companies have always been ambivalent about treatment of cigarette smokers. Tobacco-related disease accounts for roughly 8 percent of U.S. medical spending, while smoking cessation is among the most cost-effective interventions in medicine. Yet the economics look different from the perspective of an individual insurer. Treatment of tobacco use generates costs today, while many of the savings from avoiding hospitalizations, and preventing cancer and other tobacco-related diseases, accrue years …
Can health plans afford to ignore tobacco harm reduction?



















